Kelvin K Chan

Kelvin K Chan has a diverse work experience spanning multiple industries. Kelvin K co-founded Nirvana in 2019 and serves as the President, leading a mission-driven team to develop products that help individuals determine their insurance coverage for therapy and associated costs using machine-learning and data science techniques. Prior to Nirvana, Kelvin worked at Enigma from 2015 to 2019, where they held various roles including Director of Product, Manager, and Senior Associate. In these positions, they were responsible for building and scaling enterprise software powered by data science and machine-learning models for fintech, pharma, and healthcare. Kelvin also worked at IQVIA in 2013 as an Associate Consultant, where they led projects in financial diligence and market access for drugs in the health sciences sector. Additionally, they gained experience as an Analyst at IQVIA from 2013 to 2015. Earlier in their career, Kelvin worked as an Associate at Johnson & Johnson in 2012 and conducted research on Anxiety at the Eric Kandel Lab, Howard Hughes Medical Institute from 2010 to 2011. Kelvin K also conducted research on synaptic plasticity and memory at Weill Cornell Medicine from 2007 to 2010, focusing on the role of long-term potentiation in synaptic plasticity and the impact of glial cells on oxidative stress-induced neurodegeneration.

Kelvin K Chan's education history includes attending Columbia University where they obtained a BA degree in Neuroscience. Prior to that, they attended Edgemont High School for their high school education. No specific start or end years are provided for either of these educational experiences.